Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 5/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575589 | 0.89 | TGFBR1 (0.35) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL20575534 | 0.89 | SLC6A4 (0.34) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL20575901 | 0.87 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3TGFBR1NPC1 | |
| SCHEMBL20575667 | 0.85 | KDM1A (0.35) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL20575587 | 0.85 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL20575163 | 0.84 | TGFBR1 (0.33) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL20575156 | 0.84 | HTR7 (0.32) | HTR7 | |
| SCHEMBL20575191 | 0.83 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL20575637 | 0.83 | NPC1 (0.36) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL20575563 | 0.83 | KDM1A (0.34) | SLC6A2SLC6A4SLC6A3TGFBR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | SLC6A2 3506/4885SLC6A4 3203/4885SLC6A3 3576/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | SLC6A2 3506/4885SLC6A4 3203/4885SLC6A3 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.